Linagliptin Methyldimer

CAS No. 1418133-47-7

Linagliptin Methyldimer( —— )

Catalog No. M36028 CAS No. 1418133-47-7

Linagliptin Methyldimer is a potent dipeptidyl peptidase IV inhibitor, IC50=6 pM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 178 Get Quote
5MG 275 Get Quote
10MG 407 Get Quote
25MG 642 Get Quote
50MG 891 Get Quote
100MG 1152 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Linagliptin Methyldimer
  • Note
    Research use only, not for human use.
  • Brief Description
    Linagliptin Methyldimer is a potent dipeptidyl peptidase IV inhibitor, IC50=6 pM.
  • Description
    Linagliptin methyldimer is an impurity of Linagliptin. Linagliptin is a DPP-IV inhibitor, with IC50 of 1 nM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Proteasome/Ubiquitin
  • Target
    Proteasome
  • Recptor
    Proteasome
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1418133-47-7
  • Formula Weight
    945.08
  • Molecular Formula
    C50H56N16O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(C#CC)N1C2=C(N=C1N3C[C@H](N)CCC3)N(C)C(=O)N(CC4=NC(CC=5C6=C(N=C(CN7C(=O)C=8N(CC#CC)C(=NC8N(C)C7=O)N9C[C@H](N)CCC9)N5)C=CC=C6)(C)C=%10C(N4)=CC=CC%10)C2=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Pfrengle, et al. Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions as DPP-IV inhibitors. Patent. WO2013010964 A1.
molnova catalog
related products
  • 1G244

    1G244 is an inhibitor of DPP8/9 with antiatherosclerotic and antimyeloma properties. 1G244 had the IC50 values of 14 and 53 nM against DPP8 and DPP9, and The Ki values for 1G244 were 0.9 and 4.2 nM for DPP8 and DPP9

  • YU-101

    A potent, specific proteasome β5 subunit inhibitor with IC50 of 0.26 uM, 7.3 and 17.3-fold selectivity over β2i and β1i subunit, respecitvely.

  • Marizomib

    A potent, orally bioactive 20S proteasome inhibitor with IC50 of 1.3 nM.